ATE348632T1 - Prion protein peptide und deren verwendung - Google Patents

Prion protein peptide und deren verwendung

Info

Publication number
ATE348632T1
ATE348632T1 AT00941708T AT00941708T ATE348632T1 AT E348632 T1 ATE348632 T1 AT E348632T1 AT 00941708 T AT00941708 T AT 00941708T AT 00941708 T AT00941708 T AT 00941708T AT E348632 T1 ATE348632 T1 AT E348632T1
Authority
AT
Austria
Prior art keywords
prion protein
protein peptides
prp
therapeutic
antibodies specific
Prior art date
Application number
AT00941708T
Other languages
English (en)
Inventor
Neil R Cashman
Eustache Paramithiotis
Jacek Slon-Usakiewicz
Ashkan Haghighat
Marc Pinard
Trebor Lawton
Original Assignee
Caprion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22492135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348632(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caprion Pharmaceuticals Inc filed Critical Caprion Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE348632T1 publication Critical patent/ATE348632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00941708T 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung ATE348632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14063499P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
ATE348632T1 true ATE348632T1 (de) 2007-01-15

Family

ID=22492135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941708T ATE348632T1 (de) 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung

Country Status (12)

Country Link
EP (1) EP1194164B8 (de)
JP (1) JP2003521477A (de)
CN (1) CN1370078A (de)
AT (1) ATE348632T1 (de)
AU (1) AU783484B2 (de)
CA (1) CA2377648A1 (de)
DE (1) DE60032486T2 (de)
ES (1) ES2278617T3 (de)
HK (1) HK1048955A1 (de)
MX (1) MXPA01013186A (de)
NZ (1) NZ516240A (de)
WO (1) WO2000078344A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
WO2002000713A1 (en) * 2000-06-26 2002-01-03 Universität Zürich Prion-binding activity in serum and plasma determined as plasminogen and fibrinogen
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
GB2376071A (en) * 2001-05-31 2002-12-04 Mini Agriculture & Fisheries Method for typing a TSE strain
GB2379737A (en) * 2001-09-05 2003-03-19 Univ Geneve Diagnostic method for spongiform encephalopathy disease
AU2002339114A1 (en) * 2001-11-09 2003-05-19 King's College London Diagnosis demyelinating or spongiform disease
AU2003205623A1 (en) * 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
EP1382971A1 (de) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Nachweis von Prion Erkrankung
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
AU2003274368B2 (en) * 2002-10-30 2008-11-20 Proteome Sciences Plc. Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
GB0227886D0 (en) * 2002-11-29 2003-01-08 Medical Res Council Prion inhibition
PT1953551E (pt) * 2002-12-03 2014-05-06 Pathogen Removal & Diagnostic Technologies Inc Ligandos a proteína de prião e métodos de uso
US20040192887A1 (en) * 2003-03-25 2004-09-30 Ralph Zahn PH-dependent polypeptide aggregation and its use
CN1297663C (zh) * 2003-05-07 2007-01-31 中国科学院微生物研究所 一类重组基因产生的朊蛋白（PrPC）融合变构体及其用途
NZ580256A (en) 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG
EP1668369B1 (de) 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitopschutztest und verfahren zum nachweis von proteinkonformationen
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
EP1931695B1 (de) 2005-09-09 2013-04-10 Novartis AG Prionspezifische Peptoidreagentien
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
BRPI0910456A2 (pt) 2008-04-25 2016-07-19 Univ Saskatchewan petídeos imunogênicos priônicos e suas repetições
EP2128618A1 (de) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Verfahren zur Kontrolle der Präsenz von pathogenen Wirkstoffen in biologischen Flüssigkeiten durch nanostrukturierte Stoffe
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
JP2012522222A (ja) * 2009-03-25 2012-09-20 ロス アラモス ナショナル セキュリティー，エルエルシー 感染因子の急速な生前検出
EP2411800A1 (de) 2009-03-25 2012-02-01 Los Alamos National Security, LLC Faseroptische anordnung für fluoreszenzspektrometrie
CN102492018A (zh) * 2010-07-27 2012-06-13 萧乃文 酪氨酸酶多肽抑制剂
TWI419711B (zh) * 2010-07-27 2013-12-21 Univ Nat Changhua Education Tyrosinase polypeptide inhibitor
CN103460049B (zh) * 2011-01-18 2016-08-17 美国政府(由卫生和人类服务部的部长所代表) 扩增和检测朊病毒的方法
CA2877505C (en) * 2012-06-12 2020-09-22 Helix Biopharma Corp. Antibodies and conjugates that target misfolded prion protein
US9809620B2 (en) 2013-04-30 2017-11-07 University Of Saskatchewan Prion disease-specific epitopes and methods of use thereof
CN108409865A (zh) * 2018-01-19 2018-08-17 鄞州出入境检验检疫局综合技术服务中心 特异性双酚a羊多克隆抗体及其应用
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177754T1 (de) * 1991-12-03 1999-04-15 Proteus Molecular Design Fragmente von prion proteinen.
WO1993023432A1 (en) * 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
BR9610580A (pt) * 1995-09-14 2000-10-24 Univ California Anticorpos especìficos para prpse nativos
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
MXPA01013186A (es) 2002-08-12
DE60032486T2 (de) 2007-08-16
EP1194164B8 (de) 2007-03-21
HK1048955A1 (zh) 2003-04-25
AU5637500A (en) 2001-01-09
EP1194164A4 (de) 2004-09-08
WO2000078344A8 (en) 2001-11-15
AU783484B2 (en) 2005-11-03
NZ516240A (en) 2005-11-25
CN1370078A (zh) 2002-09-18
ES2278617T3 (es) 2007-08-16
EP1194164A1 (de) 2002-04-10
CA2377648A1 (en) 2000-12-28
EP1194164B1 (de) 2006-12-20
DE60032486D1 (de) 2007-02-01
WO2000078344A1 (en) 2000-12-28
JP2003521477A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
ATE348632T1 (de) Prion protein peptide und deren verwendung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE60239931D1 (de) Kombinationstherapie
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE385806T1 (de) Fusionsproteine
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP1200124A4 (de) Immunglobulin fusionsproteine
BR9707819A (pt) Imunogenos peptidicos
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE528392T1 (de) Neues protein und dessen dns
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties